Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 15/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 15/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611522 | 0.86 | KCNJ5 (0.37) | KCNJ5KCNJ3 | |
| SCHEMBL16611435 | 0.85 | KCNJ5 (0.42) | KCNJ5KCNJ3 | |
| SCHEMBL16611950 | 0.80 | RORC (0.44) | KCNJ5KCNJ3 | |
| SCHEMBL16610778 | 0.80 | KCNJ5 (0.38) | KCNJ5KCNJ3SYK | |
| SCHEMBL16611463 | 0.79 | KCNJ5 (0.37) | KCNJ5KCNJ3 | |
| SCHEMBL16611334 | 0.78 | RORC (0.46) | KCNJ5KCNJ3 | |
| SCHEMBL16610791 | 0.78 | KCNJ5 (0.36) | KCNJ5KCNJ3SYKTSHRMAPK1 | |
| SCHEMBL16611192 | 0.77 | KCNJ5 (0.39) | KCNJ5KCNJ3MAPK1 | |
| SCHEMBL16610793 | 0.76 | RORC (0.40) | KCNJ5KCNJ3 | |
| SCHEMBL16611719 | 0.75 | KCNJ5 (0.35) | KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | KCNJ5 2242/4885KCNJ3 2857/4885SYK 208/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | KCNJ5 2242/4885KCNJ3 2857/4885SYK 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.